Watch David Baker and Sharmilee Gnanapavan update us live from ECTRIMS 2019 in Stockholm. Ask your questions in the comments below or on our Youtube channel, or to @bartsmsblog on Twitter and we will try to answer you!
Watch David Baker and Sharmilee Gnanapavan update us live from ECTRIMS 2019 in Stockholm. Ask your questions in the comments below or on our Youtube channel, or to @bartsmsblog on Twitter and we will try to answer you!
Should we expect your GP or family doctor to take on more of the day-2-day management of your MS? In the UK specialist physicians are called consultants because there was always too few of them to get their hands dirty with the day-to-day management of patients with special medical problems. General practitioners used to refer their patients to a specialist for a ‘consultation’ and...
Prof G why the sudden and recent fixation with inequality? There is overwhelming evidence that many health outcomes, including life expectancy, infant mortality, obesity, cancer survival rates, suicide, addiction and many more are linked to the level of economic inequality within society. In short, greater economic inequality leads to worse health outcomes. Inequality does not necessarily refer...
This week we have had people telling us that T cells are changed in early MS (Click here) and that there were no changes in the B cells. Now we have a suggestion that B cells were active in early MS. I got excited when I saw the title about B cells in early MS. However, then I see the data, this is when I think the figures do not fit the descriptions. They fail the smack you in the eye test (The...
This post is for any health-professions who read the blog. This gives guidelines for managing thyroid problems notably after alemtuzumab 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. Muller I, Moran C, Lecumberri B, Decallonne B, Robertson N, Jones J, Dayan CM. Eur Thyroid J. 2019 Jul;8(4):173-185. Thyroid...
Disrupting Myelin-Specific Th17 Cell Gut Homing Confers Protection in an Adoptive Transfer Experimental Autoimmune Encephalomyelitis. Duc D, Vigne S, Bernier-Latmani J, Yersin Y, Ruiz F, Gaïa N, Leo S, Lazarevic V, Schrenzel J, Petrova TV, Pot C. Cell Rep. 2019; 29:378-390. Multiple sclerosis (MS) is a common autoimmune disease of the CNS. Although an association between MS and inflammatory bowel...
We all have heard about BioRXiV (Bioarchive), where people can deposit their preprints before publication on a journal. Now there is not MedRXiv (Medarchive). All that needs to be done is link this up to Pubmed and we can cut out the middle man (publisher). A free archive that is open access and you get rid of the impact factor and the publishing mess in one easy swoop. What’s not to like...
This study reports the trial of vitamin D + beta interferon verses vitamin D and the vitamin D trial fails. In my time capsule, I had this one as a fail too, just as the WORMS study failed to meet its endpoint too. You say I am saying this, after the event, which is true…but my time capsule for microbiome trials were planted about three years ago and they say the same thing. Academics are...
It is clear that many MSers on continuous anti-CD20 therapy are concerned about the risk of developing hypogammaglobulinaemia and subsequent infections. Yesterday, I spoke to several neurologists at the O’HAND investigators meeting in Barcelona who informed me that they are considering giving their ocrelizumab-treated patients hyperimmune globulin replacement therapy (HYPE-Ig-RT) when they...
This study has been sometime coming and was I think probably originally based on the idea that a worm infection can drive a TH2 (anti-inflammatory) from a TH1 (pro-inflammatory) response. I think there were a number of studies planned, but this study from Nottingham passed the finish line. In this study people were infected with the hookworm parasite and I guess became biobombs as the worms would...
I am very excited and proud to be attending and speaking at the first European Oratoria-HAND, or O’Hand, study investigator meeting in Barcelona. With Chariot-MS, the O’HAND study is the culmination of more than 4 years of work and campaigning for Barts-MS. However, our #ThinkHand campaign will only be considered a true success if we get a positive outcome from one of our studies and a DMT...